Effectiveness of convalescent plasma therapy in COVID-19 patients with haematological malignancies
==================================================================================================

* Sapha Shibeeb
* Ilham Ajaj
* Hadeel Al-Jighefee
* Atiyeh Abdallah

## Abstract

**Background** Immunocompromised patients, including those with haematological malignancies, are among the high-risk group to develop severe coronavirus disease 2019 (COVID-19) complications. The effectiveness of passive immunotherapy with convalescent plasma (CP) on such patients diagnosed with COVID-19 has not been reviewed. Therefore, the aim of this review was to systematically appraise the current evidence for the efficacy of this therapy in haematological malignancies patients with COVID-19 infection.

**Methods** A comprehensive search was conducted up-to October 2021, using four databases: PubMed, Web of Science, Science Direct, and Scopus. Two reviewers independently assessed the quality of the included studies. Data collection analysis were performed using Microsoft Excel 365 and GraphPad Prism software.

**Results** 17 studies met the inclusion criteria; these records included 258 COVID-19 patients with haematological malignancies and treated with CP therapy (CPT). The main findings from the reviewed data suggests CPT may be associated with improved clinical outcomes including (a) higher survival rate, (b) improved SARS-CoV-2 clearance and presence of detectable anti-SARS-CoV-2 antibodies post CP transfusion, (c) improved hospital discharge time, and recovery after 1 month of CP therapy. Furthermore, treatment with convalescent plasma was not associated with development of adverse events.

**Conclusion** Owing to its safety and beneficial effects in improving clinical outcomes, CPT appears to be an effective supportive therapeutic option for haematological malignancy patients infected with COVID-19.

Key words
*   Convalescent plasma
*   COVID-19
*   SARS-CoV-2
*   haematological malignancy

## Introduction

Since the first case report in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), has posed a significant challenge worldwide (1). The clinical manifestation of COVID-19 ranges from having no signs or symptoms (asymptomatic) to severe complications that include thrombosis, septic shock, acute respiratory distress syndrome (ARDS), and cardiac failure (2). Among those who are at high-risk to severe and prolonged disease course, immunocompromised patients and cancer patients (3, 4). Patients with haematological malignancies represent a distinctive subset of those vulnerable to COVID-19 and were shown to be frequently associated with high mortality and COVID-19 complications (5). Due to the underlying disease and cancer treatment, the immune system in these patients becomes impaired making them immunodeficient and prone to infection and severe disease. (2).

CPT is a form of passive immunity where plasma enriched with specific and non-specific humoral innate immunity factors is collected from recovered patients, processed, and transfused into other patients (6). During viral infection, the antibodies are key for virus opsonisation and neutralisation, in addition to the activation of complement and mediation of antibody dependent cellular cytotoxicity. This type of treatment has been previously used to treat other infectious diseases such as Ebola, SARS, Middle East respiratory syncytial virus (MERS), and influenza (2). Currently, COVID-19 has very limited treatment options, where isolation and supportive care are the major ones (7). In August 2020, the United States Food and Drug Administration (US FDA) issued an emergency use authorization (EUA) for COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19 (8). As a result, numerous trials have been conducted to assess the effectiveness of CPT in different COVID-19 patient cohorts including those with different disease severity and co-morbidities. The effectiveness of COVID-19 CPT in immunocompromised cancer patients, particularly, those with haematological malignancies has not been systematically reviewed yet. Therefore, we conducted a systematic review on the effectiveness of CPT to treat COVID-19 patients with haematological malignancies.

## Methods

The study’s focus was on haematological malignancies patients with confirmed PCR COVID-19 infection. The intervention was CPT from previously infected COVID-19 patients. The primary outcomes were (i) clinical improvement and (ii) viral clearance. The secondary outcome was adverse events after CPT. The search was conducted up-to October 2021, using four major databases; PubMed, Web of Science, ScienceDirect, and Scopus. The following terms were used; ‘COVID-19’ or ‘SARS-CoV-2’ or Coronavirus’ AND ‘convalescent plasma’ or ‘convalescent plasma therapy’. All articles were extracted and assessed by two independent authors to ensure the quality of the research. All articles were exported to Endnote X9 and all duplicates were removed.

### Inclusion and exclusion criteria

Articles were screened by title and abstracts, the following inclusion criteria were used for eligibility: 1) reported in English 2) clinical trials including, randomized and controlled clinical trials 3) prospective and retrospective comparative cohort studies, case-control studies; cross-sectional studies, case series, and case reports. Studies were excluded if they did not meet the inclusion criteria. In addition, all letters, editorials, systematic reviews, narrative reviews, abstracts, and not full-text articles were excluded. Articles published using same patient cohort were grouped and studies with largest number of patients were used.

### Quality assessment and Risk of Bias Assessment

The risk of bias for all eligible observational studies was assessed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline (9). The risk was evaluated using a previously published question tool (10), which asked questions regarding (1) Selection criteria of patients: Do all the patients meet inclusion criteria (2) Adequate ascertainment of exposure and the outcome (3) Causality: was follow-up long enough for outcomes to occur? (4) Reporting: were the case(s) described with sufficient detail to allow other investigators to replicate the research or to allow practitioners to make inferences? All studies were scored for each question as: yes (2 stars), partial (1 star), and no (0 star). An overall risk of bias was independently assigned to each eligible study by two authors. No studies rated below 5 were included in the systematic review (Table 1).

View this table:
[Table 1.](http://medrxiv.org/content/early/2022/04/10/2022.04.06.22273542/T1)

Table 1. 
Risk of Bias Assessment

View this table:
[Table 2.](http://medrxiv.org/content/early/2022/04/10/2022.04.06.22273542/T2)

Table 2. 
Summary of included studies on CPT for COVID-19 patients with haematological malignancies

### Data extraction and synthesis

The following clinical and laboratory variables were extracted: country, gender, age, type of haematological malignancy, cancer treatment, number of patients with CPT intervention, number of controls without CPT, other treatments for COVID-19. Clinical outcomes including, survival rate, adverse effect of CPT, the titter of antibody for donor and patient were recorded. Data analysis was qualitative, where the collected data were interpreted based on the presence or absence of the clinical outcomes. The findings were collected using Microsoft Excel sheets.

## Results

### Search findings

The outcome of the database search is described in a PRISMA flow chart (Figure 1). The search process yielded 2553 records, of which 578 articles were identified as duplicates and removed. Following title and abstract screening of the remaining 1975 articles, 1787 were excluded from the analysis due to one or more of the following reasons: 1) the article was published in a language other than English, 2) not original research article, 3) an animal-based study, 4) the full-text was not available, or 5) the CPT was not used as a COVID-19 treatment. From the 188 full texts screened, 171 studies were excluded because they were not conducted on patients with haematological malignancies. Seventeen studies met the inclusion criteria and were used to perform this systematic review. We identified 1103 patients, of which 258 patients had one or more haematological malignancy, diagnosed with COVID-19, and treated with CPT, whereas 845 patients were included in the control group and were provided with standard care in two of the identified studies (13, 18).

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/04/10/2022.04.06.22273542/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2022/04/10/2022.04.06.22273542/F1)

Figure 1. 
PRISMA Flow chart of study selection.

### Study characteristics and patients’ demographics

Among the 17 selected articles, 13 were case reports or case series, two were retrospective cohort studies, and two were observational multicentre studies (Table 1). The reported haematological malignancies were mainly follicular lymphoma (*n*=4), chronic lymphocytic leukaemia ((*n*=3), non-Hodgkin’s lymphoma (*n*=3), diffused large B-cell lymphoma (*n*=3), B-cell lymphoma (*n*=3), and unspecified haematological malignancies (*n*=4), (Figure 2). The range of patients age was from 9 months to 72 years, majority were older than 50 years while only three children were included (9 months, 4 and 5 years). A higher proportion of male patients were included in the studies compared to females (8:3). Ten patients had a history of receiving stem cell transplant, of which 7 were autologous transplants.

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/04/10/2022.04.06.22273542/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2022/04/10/2022.04.06.22273542/F2)

Figure 2. 
The frequency of haematological malignancies reported in the identified articles. CLL: chronic lymphocytic leukaemia, MML: myelomonocytic leukaemia, MM: multiple myeloma, HIV: human immunodeficiency virus, DLBL: diffused large B-cell lymphoma, NHL: non-Hodgkin’s lymphoma, ALL: acute lymphocytic leukaemia, FL: follicular lymphoma.

### Dose, time of administration and clinical outcomes of CPT

The dose of CP varied from 200 - 300 mL per transfusion. CPT was administered at variable time-points post hospital admission, where some patients received CPT as early as day 2-post diagnosis with COVID-19, while most of the remaining patients received CPT as a last treatment option after approximately one month of hospitalization (Table 3). In 14 studies, the total number of administered CPT doses ranged between 1-3 doses, however, two 53-year old patients diagnosed with lymphoma were administered 8 and 12 doses (2, 16) due to their poor response to the initial treatment.

View this table:
[Table 3.](http://medrxiv.org/content/early/2022/04/10/2022.04.06.22273542/T3)

Table 3. 
Summary of clinical outcomes from selected articles.

Different clinical outcome parameters were assessed in patients following CPT, but the most common reported outcomes were mortality, development of adverse events to CPT, clearance of SARS-CoV-2 infection, and cease of COVID-19 symptoms. Mortality was reported in 56 (21.7%) patients who received CPT and in 213 (25.2%) control patients who received the standard care. Adverse events to CPT were reported in only three patients who developed febrile non-haemolytic transfusion reaction. Other treatments that were administered to patients along with CPT including oxygen therapy, steroids, Azithromycin, Hydroxychloroquine, and Remdesivir.

The use of CPT is associated with improved overall survival (OR: 1.41, 95%CI: 0.99-1.99), viral clearance, (OR: 2.0, 95%CI: 1.04-2.08), detection of anti-SARS-CoV-2 antibodies in the patient’s plasma post CPT (OR: 6.33 95%CI: 1.7-17.3), hospital discharge (OR: 3.0 95%CI: 1.3-5.6), and recovery after 1 month of CPT (OR: 1.75 95%CI: 1.1-2.8). Further, the probability of developing adverse event in these patients due to CPT were significantly lower compared to the control group (OR: 0.24 95%CI: 0.14-0.40) (Figure 3).

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/04/10/2022.04.06.22273542/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2022/04/10/2022.04.06.22273542/F3)

Figure 3. 
Odds ratio for the effectiveness of CPT on clinical outcome of patients with haematological malignancies and diagnosed with COVID-19.

## Discussion

Our analysis of the efficacy of using CPT from previously infected COVID-19 donors to treat COVID-19 infected patients with haematological malignancy suggests that CPT may reduce mortality rate and improve viral clearance.

A study by Borah *et al*. (25) reported a 60% mortality rate in haematological malignancies patients with severe COVID-19 infection. The efficacy of CPT to reduce the mortality rate was reported in four of the 17 studies, however, only two studies compared the percentage of mortality to the control group. Thompson *et al*. reported a mortality rate of 13.1% in the CPT recipient group and 24.8% in the non-recipient group, moreover, the mortality rate was significantly lower in intensive care unit patients on mechanical ventilation (26). Furthermore, another study demonstrated a mortality rate of 13% among the CPT recipient group compared to a mortality rate of 41% in the non-recipient group.

(27).

A recent meta-analysis reported that using CPT could significantly reduce the risk of mortality in covid-19 patients compare to those without CPT(28). Jeyaraman *et al*. (23)and Tremblay *et al*. (7) reported a mortality rate of 45.5% and 35.7%, respectively. However, the efficacy of CPT to reduce mortality in these two studies is difficult to ascertain due to the lack of a control group. Abeldaño Zuñiga *et al*. (29) concluded that using CPT for hospitalized COVID-19 patients could result in clinical improvement for patients, however, it does not significantly lower mortality rate in comparison to standard care and placebo.

Most of the included articles in our analysis reported significant improvement in patient status after CPT, patients become asymptomatic and were discharged. Four articles reported improved viral clearance after using CPT (17-20). Similarly, Sarkar *et al*. (30) concluded from 7 studies that CPT can enhance viral clearance and improve patient outcomes. on the other hand, a meta-analysis that included 5 RCTs, 6 cohort studies, and 16 case studies reported that using CPT in moderate and severe hospitalisedCOVID-19 patients does not affect the clinical outcome (31). However, in this meta-analysis the patients did not present with haematological malignanices and so they could have produced anti-SARS-CoV-2 antibodies, hence CPT intervention did not significantly improve their outcome.

In all reviewed articles, we found that CPT is safe with no adverse reactions reported in patients with haematological\ malignancies presenting with severe COVID-19 infection. However, one of the included studies reported febrile non-haemolytic transfusion reaction (FNHTR) in three patients post CPT (7). Supporting our findings, a recent mata-anlysis concluded that CPT is a safe approach for COVID-19 patient therapy where only 3.5% of recipients patients had developed an adverse effect (32). Nevertheless, a living systematic review stated that it is difficult to determine whether the adverse effect is due to the patient’s condition or CPT (33). Therefore, more studies are required to investigate the safety of CPT in COVID-19 infected cancer patients.

A minimum of one ABO compatible CP dose was given to patients, with most received 1 to 2 doses. However, one patient with diffuse large B-cell lymphoma (DLBCL) who had a prolonged active COVID-19 infection for 129 days, received 8 doses of CP until remission (34). There are no recommended or standardized doses of CP, however, most of the studies used one to two-units and the titer of the antibody might determine the optimal dose (35). In our study, only four papers measured the titer of the donor antibodies before transfusion (7, 17, 20, 24). One of the included retrospective multicentre observational studies found that there was no significant differences in moratlity in patients who received one versus two-dose of CP or in patients who received early versus late transfusion of CP (23).

In all 17 studies, standard care including supportive care and antiviral therapy with hydroxychloroquine, azithromycin, and/or ritonavir, and Tocilizumab (for very critical patients) were given to patients before initiating CPT. In addition, most of the patients required oxygen therapy. Duan et al. reported that CPT combined with supportive care and antiviral therapy can improve the clinical outcome of COVID-19 patients (36). Additionally, Agarwal *et al*. reported that using CPT alone might not be effective in reducing the severity, risk of mortality, and period of hospitalization of COVID-19 patients (37). Therefore, it is recommended to use CPT therapy with the combination of treatment to achieve the optimal result.

To the best of our knowledge, this is the first systematic review to discuss the efficacy and safety of CPT in patients with haematological malignancies presenting with severe COVID-19 complications. However, this review includes some limitations, including heterogeneity, lack of control group in most of the included studies, and randomized control trials. The heterogeneity of CPT dose, time of transfusion, reported outcome such as viral clearance, donor antibody titters, and lack of control groups to compare the result made it difficult to preform a meta-analysis.

## Conclusion

This review demonstrates that CPT is an effective and safe supportive therapy for patients with haematological malignancies and diagnosed with COVID-19 infection. The exact mechanism by which CPT may have mediated improved outcomes in the treated patients is likely multifactorial and could include reduction in viral load via enhanced clearance. Further studies and analysis are needed to fully understand the effectiveness of CPT in cancer patients with COVID-19.

## Data Availability

All data is available within the manuscript

## CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

*   Received April 6, 2022.
*   Revision received April 6, 2022.
*   Accepted April 10, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## Reference

1.  1.Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. Author Correction: A new coronavirus associated with human respiratory disease in China. Nature. 2020;580(7803):E7–E.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F10%2F2022.04.06.22273542.atom) 

2.  2.Rnjak D, Ravlić S, Šola AM, Halassy B, Šemnički J, Šuperba M, et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? Transfus Clin Biol. 2021;28(3):264–70.
    
    

3.  3.Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020;35(3):266–71.
    
    

4.  4.Decker A, Welzel M, Laubner K, Grundmann S, Kochs G, Panning M, et al. Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. American Journal of Transplantation. 2020;20(11):3239–45.
    
    

5.  5.Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet. 2020;395(10241):1907–18.
    
    

6.  6.Shankar R, Radhakrishnan N, Dua S, Arora S, Rana M, Sahu DK, et al. Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. Transfus Apher Sci. 2021;60(1):102956.
    
    

7.  7.Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Med. 2020;9(22):8571–8.
    
    

8.  8.Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discovery Today. 2021;26(2):593–603.
    
    

9.  9.Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bulletin of the World Health Organization. 2007;85:867–72.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2471/BLT.07.045120&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18038077&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F10%2F2022.04.06.22273542.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000250858300014&link_type=ISI) 

10. 10.Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. The Pediatric infectious disease journal. 2020;39(11):e340–e6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0000000000002888&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F10%2F2022.04.06.22273542.atom) 

11. 11.Szwebel TA, Veyer D, Robillard N, Eshagh D, Canoui E, Bruneau T, et al. Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. Stem Cell Rev Rep. 2021;17(1):296–9.
    
    

12. 12.Wright Z, Bersabe A, Eden R, Bradley J, Cap A. Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(1):66–8.
    
    

13. 13.Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology. 2021;7(8):1167–75.
    
    

14. 14.Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, et al. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv. 2020;4(19):4864–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1182/BLOODADVANCES.2020002595&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F10%2F2022.04.06.22273542.atom) 

15. 15.Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep. 2020;21:e927812.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.12659/AJCR.927812&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33009361&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F10%2F2022.04.06.22273542.atom) 

16. 16.Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis. 2020.
    
    

17. 17.Balashov D, Trakhtman P, Livshits A, Kovalenko I, Tereshenko G, Solopova G, et al. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. Transfusion and Apheresis Science. 2021;60(1):102983.
    
    

18. 18.Biernat MM, Kolasińska A, Kwiatkowski J, Urbaniak-Kujda D, Biernat P, Janocha-Litwin J, et al. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. Viruses. 2021;13(3).
    
    

19. 19.Çınar OE, Sayınalp B, Aladağ Karakulak E, Avsar Karatas A, Velet M, İnkaya AÇ, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfusion and Apheresis Science. 2020;59(5):102821.
    
    

20. 20.Dell’Isola GB, Felicioni M, Ferraro L, Capolsini I, Cerri C, Gurdo G, et al. Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection. Frontiers in Pediatrics. 2021;9(777).
    
    

21. 21.Ferrari S, Caprioli C, Weber A, Rambaldi A, Lussana F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma. 2021;62(6):1490–6.
    
    

22. 22.Hueso T, Pouderoux C, Péré H, Beaumont A-L, Raillon L-A, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–5.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F10%2F2022.04.06.22273542.atom) 

23. 23.Jeyaraman P, Agrawal N, Bhargava R, Bansal D, Ahmed R, Bhurani D, et al. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. Transfusion and Apheresis Science. 2021;60(3):103075.
    
    

24. 24.Karatas A, İnkaya AÇ, Demiroğlu H, Aksu S, Haziyev T, Çınar OE, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci. 2020;59(5):102871-.
    
    

25. 25.Borah P, Mirgh S, Sharma SK, Bansal S, Dixit A, Dolai TK, et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells, Molecules, and Diseases. 2021;87:102525.
    
    

26. 26.Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19. JAMA Oncology. 2021;7(8):1167–75.
    
    

27. 27.Biernat MM, Kolasinska A, Kwiatkowski J, Urbaniak-Kujda D, Biernat P, Janocha-Litwin J, et al. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. VIRUSES-BASEL. 2021;13(3).
    
    

28. 28.Wardhani SO, Fajar JK, Wulandari L, Soegiarto G, Purnamasari Y, Asmiragani A, et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: A meta-analysis. F1000Research. 2021;10.
    
    

29. 29.Abeldaño Zuñiga RA, Coca SM, Abeldaño GF, González-Villoria RAM. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. Therapeutic Advances in Respiratory Disease. 2021;15.
    
    

30. 30.Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. Journal of Medical Virology. 2021;93(2):1111–8.
    
    

31. 31.Piscoya A, Ng-Sueng LF, Parra Del Riego A, Cerna-Viacava R, Pasupuleti V, Thota P, et al. Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis. Arch Med Sci. 2021;17(5):1251–61.
    
    

32. 32.Barreira DF, Lourenço RA, Calisto R, Moreira-Gonçalves D, Santos LL, Videira PA. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 2021;8:378.
    
    

33. 33.Valk SJ, Piechotta V, Kimber C, Chai KL, Monsef I, Doree C, et al. Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2. Cochrane Database of Systematic Reviews. 2021;2020(12).
    
    

34. 34.Rnjak D, Ravlić S, Šola AM, Halassy B, Šemnički J, Šuperba M, et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? Transfusion Clinique et Biologique. 2021;28(3):264–70.
    
    

35. 35.1.  Kleinman S, 
    2.  Tirnauer JS, 
    3.  Feldweg TM, editors
    
    Bloch EM. COVID-19: Convalescent plasma and hyperimmune globulin. In: Kleinman S, Tirnauer JS, Feldweg TM, editors. UpToDate, Waltham, MA. 2021.
    
    

36. 36.Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(17):9490–6.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiMTE3LzE3Lzk0OTAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wNC8xMC8yMDIyLjA0LjA2LjIyMjczNTQyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

37. 37.Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). Bmj. 2020;371:m3939.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzEvb2N0MjJfOC9tMzkzOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA0LzEwLzIwMjIuMDQuMDYuMjIyNzM1NDIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)